CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index; 27 of the 57 sources its claims cite were checked for support.

The European Biological Variation Study (EuBIVAS): a summary report

Open access
Carobene, Anna, Aarsand, Aasne K., Bartlett, William A., Coskun, Abdurrahman, Diaz-Garzon, Jorge, Fernandez-Calle, Pilar, Guerra, Elena, Jonker, Niels, Locatelli, Massimo, Plebani, Mario, Sandberg, Sverre, Ceriotti, Ferruccio · 2022 · Clinical Chemistry and Laboratory Medicine (CCLM)

Abstract

Biological variation (BV) data have many important applications in laboratory medicine. Concerns about quality of published BV data led the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 1st Strategic Conference to indicate need for new studies to generate BV estimates of required quality. In response, the EFLM Working Group on BV delivered the multicenter European Biological Variation Study (EuBIVAS). This review summarises the EuBIVAS and its outcomes. Serum/plasma samples were taken from 91 ostensibly healthy individuals for 10 consecutive weeks at 6 European centres. Analysis was performed by Siemens ADVIA 2400 (clinical chemistry), Cobas Roche 8000, c702 and e801 (proteins and tumor markers/hormones respectively), ACL Top 750 (coagulation parameters), and IDS iSYS or DiaSorin Liaison (bone biomarkers). A strict preanalytical and analytical protocol was applied. To determine BV estimates with 95% CI, CV-ANOVA after analysis of outliers, homogeneity and trend analysis or a Bayesian model was applied. EuBIVAS has so far delivered BV estimates for 80 different measurands. Estimates for 10 measurands (non-HDL cholesterol, S100-β protein, neuron-specific enolase, soluble transferrin receptor, intact fibroblast growth-factor-23, uncarboxylated-unphosphorylated matrix-Gla protein, human epididymis protein-4, free, conjugated and %free prostate-specific antigen), prior to EuBIVAS, have not been available. BV data for creatinine and troponin I were obtained using two analytical methods in each case. The EuBIVAS has delivered high-quality BV data for a wide range of measurands. The BV estimates are for many measurands lower than those previously reported, having an impact on the derived analytical performance specifications and reference change values.

Overview

CoChat Summary

TL;DR

The EuBIVAS multicenter study collected weekly serum/plasma samples from 91 ostensibly healthy individuals over 10 consecutive weeks at six European centers to generate high-quality biological variation (BV) estimates. It has delivered BV estimates for 80 measurands, including 10 previously unavailable, with many estimates lower than historical data and implications for analytical performance specifications (APS) and reference change values (RCVs).

Key findings

  • EuBIVAS delivered BV estimates for 80 measurands; 10 had no prior published estimates: non-HDL cholesterol, S100β protein, neuron-specific enolase, soluble transferrin receptor, intact fibroblast growth-factor-23, uncarboxylated-unphosphorylated matrix-Gla protein, human epididymis protein-4, and free, conjugated and %free prostate-specific antigen.
  • For many measurands, EuBIVAS BV estimates were lower than previously reported, producing stricter APS and smaller RCVs; for common measurands such as albumin, creatinine, urea, chloride, sodium, potassium, lipids and glucose, EuBIVAS did not really change prior estimates.
  • About 25% of participants had at least one mild inflammation episode during the 10 weeks; exclusions for proteins ranged from 4.9% for β2-microglobulin to 20% for haptoglobin. For 25(OH)D, no steady state was found; concentrations increased by 2.8% weekly over spring and by 31.6% after 10 weeks, with proposed measurement uncertainty thresholds of <1.2% for higher-order reference methods and <13.6% for routine assays to detect an increase at p<0.05 (9.6% at p<0.01).
  • EuBIVAS is fully BIVAC compliant and elicited grade A; systematic reviews found only 3/61 kidney-related, 1/59 lipid, 1/47 diabetes-related, 6/16 cardiac troponin and 4/49 tumor marker papers fully BIVAC compliant, with all A-graded tumor marker publications derived from EuBIVAS.

Methods

  • Multicenter study at six European laboratories (Milan, Bergen, Madrid, Padua, Istanbul, Assen); 105 subjects were recruited, 97 volunteers were sampled, and the final CV-ANOVA population was 91 subjects (38 men, 43 women in fertile age, 10 women above 50 years identified as menopausal). Fasting blood samples were drawn weekly for 10 consecutive weeks (April–June 2015), providing serum, K2EDTA-plasma and citrated-plasma samples; a biobank of 18,000 aliquots was established.
  • Analyses used Siemens ADVIA 2400 (clinical chemistry), Cobas Roche 8000 c702 and e801 (proteins and tumor markers/hormones), ACL Top 750 (coagulation parameters), and IDS iSYS or DiaSorin Liaison (bone biomarkers); all samples from the same participant were analyzed in duplicate within a single run under a strict preanalytical and analytical protocol.
  • BV estimates were mostly obtained by the Røraas method based on CV-ANOVA after outlier, homogeneity and trend analysis; a Bayesian approach was applied for coagulation parameters. CVG was calculated on natural log-transformed data, RCVs used the log-normal approach, and subgroup analyses were performed by sex, age and country where relevant.

Limitations

  • Stated by the authors: the small number of menopausal women (n=10) is an undoubted limitation; estimates from women >50 years were not used for APS calculations, and if significant differences exist between pre- and postmenopausal women, estimates from this small subgroup may not reliably characterize them.
  • Stated by the authors: the classical BV model was inappropriate for 25(OH)D and inflammatory marker proteins; for 25(OH)D more than 50% of data were eliminated, and after MoM transformation more than 40% were still eliminated, while high exclusions for proteins such as haptoglobin may have limited generalizability and caused underestimation of BV.
  • Stated by the authors: most available BV data are derived from healthy adults, and further studies are required for children, elderly and patients with relevant disease states. Evident from the text: as a summary report, detailed per-measurand methods and results are deferred to prior EuBIVAS publications.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1515/cclm-2021-0370

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

18 Valid · 2 Not valid · 20 Not checked · 48 Own results and interpretations

47 more claims · 10 with their cited sources checked

Create a free account to see all 88 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 2

  1. Fraser, CG. The nature of biological variation. In: biological variation: from principles to practice. Washington, DC: AACC Press; 2001:1–27 pp.
  2. Fraser, CG. Biological variation in clinical chemistry. Arch Pathol Lab Med 1992;116:916–23.

Cited by

See all 84

Metadata

Authors
Carobene, A., Aarsand, A. K., Bartlett, W. A., Coskun, A., Diaz-Garzon, J., Fernandez-Calle, P., Guerra, E., Jonker, N., Locatelli, M., Plebani, M., Sandberg, S., & Ceriotti, F.
Affiliations
  • IRCCS Ospedale San Raffaele (IT)
  • Haukeland University Hospital (NO)
  • University of Dundee (GB)
  • Acibadem Mehmet Ali Aydınlar University, School of Medicine , Istanbul , Turkey
  • Hospital Universitario La Paz, and Quality Analytical Commission of Spanish Society of Laboratory Medicine (SEQC ) , Madrid , Spain
  • Stichting Certe Medische Diagnostiek en Advies (NL)
  • University of Padua (IT)
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Corresponding author
Carobene, Anna
Venue
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2021-05-31
Volume
60
Issue
4
Pages
505-517
ISSN
  • 1434-6621 (ISSN-L)
  • 1437-4331
OpenAlex
W3165813453
Cited by
84
References
48
Citations by year
2026: 12 · 2025: 12 · 2024: 18 · 2023: 16 · 2022: 17 · 2021: 9
FWCI
3.75
Type
journal article
Language
en
Open access
Locations
  • Clinical Chemistry and Laboratory Medicine (CCLM) (publishedVersion)
  • PubMed (publishedVersion)
  • Acibadem University Open Access Repository (submittedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
Topics
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
  • Physical Sciences › Physics and Astronomy › Instrumentation › Scientific Measurement and Uncertainty Evaluation
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Reliability and Agreement in Measurement
Keywords
biological variation, reference values, healthy volunteers, Bayesian model, reference change value, analytical performance specifications, tumor markers, bone turnover markers, coagulation parameters, prostate-specific antigen, fibroblast growth factor 23, matrix Gla protein, creatinine, troponin I
MeSH terms
Bayes Theorem, Chemistry, Clinical, Creatinine, Humans, Male, Multicenter Studies as Topic, Prostate-Specific Antigen, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The European Biological Variation Study (EuBIVAS): a summary report. https://app.cochat.ai/papers/10.1515/cclm-2021-0370
The paper
Carobene, A., Aarsand, A. K., Bartlett, W. A., Coskun, A., Diaz-Garzon, J., Fernandez-Calle, P., Guerra, E., Jonker, N., Locatelli, M., Plebani, M., Sandberg, S., & Ceriotti, F. (2022). The European Biological Variation Study (EuBIVAS): a summary report. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2021-0370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.